Brief: PCI Biotech Holding Says Efforts To Finance Planned Ph II Trial Have Not Resulted In Way Forward

PCI Biotech Holding ASA

18/08/2022 17:10

Aug 18 (Reuters) - PCI Biotech Holding ASA  PCIB.OL :
    * PCI BIOTECH HOLDING - EFFORTS TO FINANCE PLANNED PH II
TRIAL IN
HEAD AND NECK CANCER HAVE NOT UNDER CURRENT MARKET CONDITIONS
RESULTED IN WAY FORWARD
    * CASH POSITION PER Q2 2022 IS AROUND NOK 76 MILLION AND
FINANCIAL
RUNWAY IS ESTIMATED TO BE TOWARDS END OF 2023
    * WILL NOT CONDUCT COMPANY-SPONSORED PH II TRIAL WITH
FIMAVACC
TECHNOLOGY REDUCTION OF CLINICAL TEAM WILL BE ENACTED DURING H2
2022

Source text for Eikon:  ID:nGNE6rJLD7 
Further company coverage:  PCIB.OL 

 ((Reuters.Briefs@thomsonreuters.com;))